Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib in advanced colorectal cancer
NCT02314819Phase 3Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Dec 2014
- Primary completion
- Jan 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of fruquintinib in colorectal cancer (CRC), sponsored by Hutchison MediPharma (HMP). Started Dec 2014; status: completed.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02314819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02314819.